Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

BACKGROUND: Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA). This multicenter, phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study investigated the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Alten, Rieke, Gomez-Reino, Juan, Durez, Patrick, Beaulieu, Andre, Sebba, Anthony, Krammer, Gerhard, Preiss, Ralph, Arulmani, Udayasankar, Widmer, Albert, Gitton, Xavier, Kellner, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152943/
https://www.ncbi.nlm.nih.gov/pubmed/21736751
http://dx.doi.org/10.1186/1471-2474-12-153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152943/
https://www.ncbi.nlm.nih.gov/pubmed/21736751
http://dx.doi.org/10.1186/1471-2474-12-153

Ejemplares similares